Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1] Group 1: Cash Management Approval - The board of directors and the supervisory board approved the cash management proposal during meetings held from January 20 to 22, 2025 [1] - The cash management usage period is valid for 12 months from the date of board approval, with the option for rolling use [1] Group 2: Redemption and Returns - Fujian Tongchun used 40 million yuan of temporarily idle funds to purchase a structured deposit from China Merchants Bank, which matured on July 31, 2025, yielding a return of 46,000 yuan [2] - The principal and returns from the structured deposit have been returned to the dedicated fundraising account [2] Group 3: Recent Cash Management Activities - In the last 12 months, the company has invested a total of 202.9 million yuan in various cash management products, with a total return of 227,490 yuan [3] - The highest single-day investment in the last 12 months was 70 million yuan, representing 10.24% of the audited net assets for the past year [3] Group 4: Current Cash Management Status - The total cash management limit is 70 million yuan, with 46.2 million yuan already utilized and 23.8 million yuan remaining available for use [4]